Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Thursday, BTIG maintained its Buy rating on Vaxcyte (NASDAQ:PCVX) with a price target of $160.00. The firm's positive stance comes as the Advisory Committee on Immunization Practices (ACIP) presented coverage data for VAX-31, Vaxcyte's lead vaccine candidate, indicating its potential to be more efficacious than existing options. The ACIP's decision reflects a need for effective vaccines and promising candidates in development.
The ACIP's recent discussions and financial analysis highlighted the cost per Quality Adjusted Life Year (QALY) for current vaccines, which appears high compared to the accepted cost-effectiveness range of $50,000-$60,000/QALY. VAX-31 could potentially offer broader coverage and cost less than $250 per dose, which are significant improvements over current vaccines. A formal recommendation by the Centers for Disease Control and Prevention (CDC) is necessary for the ACIP's recommendation to have a substantial effect.
Vaxcyte's VAX-31 may benefit from a general age-based recommendation, which could lead to wider use compared to vaccines like PCV20 that are recommended for specific risk groups. Currently, PCV20 is advised for approximately half of the individuals aged 50 and above with a risk factor for invasive pneumococcal disease, but this has resulted in limited uptake compared to the broader recommendation for those over 65.
Patient-level safety data remains a key unknown for Vaxcyte's vaccine candidate. While population-wide data suggests that VAX-31 has comparable safety to PCV20, the forthcoming details are anticipated with interest. In terms of competition, BTIG sees no significant threat from other vaccines in their current forms. Innovations like the use of new vaccine adjuvants, such as those explored by Novavax (NASDAQ:NVAX), could improve vaccine efficacy but may also affect tolerability. Early safety data from these explorations are expected to provide insights.
In other recent news, Vaxcyte has been the subject of numerous positive analyst reports following promising results from its pneumococcal conjugate vaccine candidate, VAX-31. TD Cowen maintained a Buy rating on the company, citing the vaccine's potential to provide broader protection against invasive pneumococcal disease compared to current market leaders. Similarly, Mizuho and BofA Securities increased their price targets for Vaxcyte, while maintaining Outperform and Buy ratings respectively.
Vaxcyte's recent success is also reflected in the company's financial strides. Vaxcyte recently completed a significant public offering, raising approximately $1.5 billion. The offering was managed by several financial institutions, including BofA Securities, Jefferies, and Goldman Sachs & Co. LLC. This funding is expected to support the continued development of Vaxcyte's vaccine candidates.
In addition to these developments, Vaxcyte has made changes to its corporate structure with the recent appointment of John P. Furey to its Board of Directors. These recent developments highlight Vaxcyte's progress in its mission to develop vaccines against bacterial infections, with plans to progress VAX-31 into Phase 3 trials for adult indication by mid-2025.
InvestingPro Insights
As Vaxcyte (NASDAQ:PCVX) continues to make strides with its VAX-31 vaccine candidate, recent financial data from InvestingPro offers additional context to the company's market position. Despite not being profitable over the last twelve months, Vaxcyte has seen a remarkable 132.99% price total return over the past year, reflecting investor optimism about its potential.
An InvestingPro Tip highlights that Vaxcyte holds more cash than debt on its balance sheet, which could provide financial flexibility as it progresses through clinical trials and potential commercialization of VAX-31. This strong cash position aligns with the company's need for resources to support its vaccine development efforts.
Another relevant InvestingPro Tip notes that Vaxcyte's liquid assets exceed short-term obligations, suggesting a solid financial foundation to sustain its operations and research initiatives. This financial stability is crucial as the company awaits potential CDC recommendations and navigates the competitive landscape of vaccine development.
For investors seeking a deeper understanding of Vaxcyte's financial health and market potential, InvestingPro offers 9 additional tips that could provide valuable insights into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.